Duchenne muscular dystrophy (DMD)

boardroom
Biotech

Keros shakes up leadership structure to go all in on DMD drug

Keros shook up its leadership structure as the biotech attempts to shake off the failure of its blood pressure drug by going all in on a DMD asset.
James Waldron Aug 7, 2025 6:15am
sarepta building
Favicon Fierce Pharma

FDA backtracks on Sarepta's gene therapy Elevidys in DMD

Jul 28, 2025 6:02pm
Redbrick building with Sarepta name and logo
Favicon Fierce Pharma

FDA contemplates pulling Sarepta’s Elevidys from market

Jul 18, 2025 3:10pm
Businessman about to be crushed by falling dominos

Sarepta overhaul includes 500 layoffs, gene therapy program cuts

Jul 16, 2025 4:59pm
Graphic image of a red thumbs down against a blue background

FDA rejects Capricor’s DMD cell therapy, asks for more data

Jul 11, 2025 9:18am
Goal disorientation and lack of vision

UPDATED: Taiho’s discontinues ph. 3 trial after DMD miss

Jul 8, 2025 10:17am